"10.1371_journal.pone.0011310","plos one","2010-06-25T00:00:00Z","Johan Lindberg; Carla A Wijbrandts; Lisa G van Baarsen; Gustavo Nader; Lars Klareskog; Anca Catrina; Rogier Thurlings; Margriet Vervoordeldonk; Joakim Lundeberg; Paul P Tak","Department of Gene Technology, School of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden; Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden","Conceived and designed the experiments: JL LK JL PPT. Performed the experiments: JL. Analyzed the data: JL LvB GAN. Contributed reagents/materials/analysis tools: JL CW AIC RT MJV. Wrote the paper: JL CW LvB LK JL PPT.","P.P. Tak has served as a consultant for Abbott, Amgen, Centocor, Schering-Plough, UCB, and Wyeth. Patients were treated with infliximab, a commercial antibody marketed by Schering-Plough. There are no patents, marketed products, or products in development related to this research. Also, the use of infliximab does not alter the adherence of this work to all the PLoS ONE policies on sharing data and materials.","2010","06","Johan Lindberg","JL",10,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
